ÌÇÐÄvlog

This Viewpoint describes the advent of neonatal neurocritical care training, the data supporting the need and its efficacy, and the ways this training can optimize outcomes for vulnerable patients and their families.

This essay describes the efforts patients might make to hold onto their humanity in the midst of an absurd world: being in the emergency department with a neurological injury.

This cohort study investigates if prehospital management in a mobile stroke unit compared with standard emergency medical services management reduces the level of global disability at hospital discharge in patients with ischemic stroke who are potentially eligible for intravenous thrombolysis.

This Viewpoint discusses using digital biomarkers for neurodegenerative disease.

This study attempts to develop and externally validate a prognostic score to estimate the individual risk of postcerebral venous thrombosis epilepsy.

This systematic review and meta-analysis evaluates the risk of new-onset inflammatory central nervous system diseases after tumor necrosis factor–inhibitor treatment for autoimmune disease.

This cohort study analyzes electronic health record data for US veterans with an audiogram to determine whether hearing loss is associated with an increased risk of Parkinson disease and to gauge its effect modification by well-established prodromal conditions and hearing aids.

This cohort study examined the yield and use of genome sequencing after nondiagnostic exome sequencing for pediatric patients with unexplained epilepsy between August 2018 and May 2023.

This Viewpoint advocates for the implementation of collaborative care with care navigation in the diagnosis and treatment of Alzheimer disease.

This diagnostic study evaluates the ability of multiple skin biopsies to detect prion seeding activity compared with the cerebrospinal fluid (CSF) as a diagnostic biomarker in prion diseases.

This case report describes a novel crossed clonus response in a 48-year-old man with compressive cervical myelopathy.

This Viewpoint advocates for the accelerated adoption of tofersen therapy to treat patients with variant SOD1-mediated amyotrophic lateral sclerosis (ALS) and describes the current barriers to treatment.